16 reports of this reaction
2.3% of all NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE reports
#10 most reported adverse reaction
HYPOACUSIS is the #10 most commonly reported adverse reaction for NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE, manufactured by Amneal Pharmaceuticals NY LLC. There are 16 FDA adverse event reports linking NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE to HYPOACUSIS. This represents approximately 2.3% of all 690 adverse event reports for this drug.
Patients taking NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE who experience hypoacusis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOACUSIS is a less commonly reported adverse event for NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE, but still significant enough to appear in the safety profile.
In addition to hypoacusis, the following adverse reactions have been reported for NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE:
The following drugs have also been linked to hypoacusis in FDA adverse event reports:
HYPOACUSIS has been reported as an adverse event in 16 FDA reports for NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOACUSIS accounts for approximately 2.3% of all adverse event reports for NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE, making it a notable side effect.
If you experience hypoacusis while taking NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND HYDROCORTISONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.